ReviewCancer biology & medicine2021
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Review in Cancer biology & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Cutaneous T Cell Lymphoma: Targeting the Survival Network in Mycosis Fungoides and Sézary Syndrome.Cancers · 2026Review
- Review
- Macrophage polarization in hematologic cancers: mechanisms and therapeutic strategies.Blood research · 2026Review
- Classical and biological treatments in mycosis fungoides/Sézary syndrome. New horizons in oncodermatology.Postepy dermatologii i alergologii · 2025Review
- New and emerging therapies in cutaneous T-cell lymphoma.Dermatology reports · 2025Article
- Targeting the Epigenome Reduces Keloid Fibroblast Cell Proliferation, Migration, and Invasion.The Journal of investigative dermatology · 2025Article
- Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes.Animals : an open access journal from MDPI · 2023Review
- Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma.Frontiers in immunology · 2023Review
- Single-cell analyses reveal novel molecular signatures and pathogenesis in cutaneous T cell lymphoma.Cell death & disease · 2022Article
- Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.International journal of molecular sciences · 2022Review
- Emerging drugs for the treatment of cutaneous T-cell lymphoma.Expert opinion on emerging drugs · 2022Review
- DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitorsFrontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. There are limited options for effective treatment of patients with advanced-stage CTCL, leading to a poor survival rate. Epigenetics plays a pivotal role in regulating gene expression without altering the DNA sequence. Epigenetic alterations are involved in virtually all key cancer-associated pathways and are fundamental to the genesis of cancer. In recent years, the epigenetic hallmarks of CTCL have been gradually elucidated and their potential values in the diagnosis, prognosis, and therapeutic intervention have been clarified. In this review, we summarize the current knowledge of the best-studied epigenetic modifications in CTCL, including DNA methylation, histone modifications, microRNAs, and chromatin remodelers. These epigenetic regulators are essential in the development of CTCL and provide new insights into the clinical treatments of this refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.